CorMedix Inc. Announces New Commercial Agreement To Provide Access To DefenCath For Adult Patients With Kidney Failure Receiving Hemodialysis Through A Central Venous Catheter At More Than 250 Outpatient Dialysis Clinics Located Across The United States
CorMedix Inc. Announces New Commercial Agreement To Provide Access To DefenCath For Adult Patients With Kidney Failure Receiving Hemodialysis Through A Central Venous Catheter At More Than 250 Outpatient Dialysis Clinics Located Across The United States
CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a new commercial supply contract with a top-tier mid-sized dialysis operator for the supply of DefenCath (taurolidine and heparin) to dialysis clinics in the US. This new agreement will provide access to DefenCath for adult patients with kidney failure receiving hemodialysis through a central venous catheter at more than 250 outpatient dialysis clinics located across the United States.
cormedix公司（納斯達克股票代碼:CRMD）是一家專注於開發治療致命疾病的生物製藥公司，今天宣佈公司已與一家頂尖中等規模的透析運營商簽訂了新的商業供應合同，爲美國的透析診所提供DefenCath（他羅啉和肝素）的供貨。這項新協議將爲美國250多家分佈在全美的門診透析診所的接受透析治療、使用中央靜脈導管的腎衰竭成年患者提供對DefenCath的使用機會。
CorMedix received NDA approval of DefenCath under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) on November 15, 2023, and began commercialization of the product in the inpatient setting on April 15, 2024. Outpatient reimbursement of DefenCath from the Center for Medicare & Medicaid Services (CMS) took effect on July 1st, and CorMedix subsequently commenced the shipment of orders to outpatient dialysis facilities in July. CorMedix anticipates shipments for DefenCath under this agreement to begin in the beginning of the fourth quarter.
cormedix已於2023年11月15日獲得了DefenCath在有限人群途徑的抗菌和抗真菌藥物（LPAD）下的新藥申請批准，並於2024年4月15日開始在住院環境中進行該產品的商品化。來自康哲藥業（CMS）的DefenCath門診報銷政策從7月1日起生效，公司隨後在7月開始向門診透析設施發貨。cormedix預計根據該協議的DefenCath發貨將於第四季度初開始。
